Medical - Devices
Compare Stocks
5 / 10Stock Comparison
STE vs CNMD vs HOLX vs MMSI vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Devices
STE vs CNMD vs HOLX vs MMSI vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $21.00B | $1.17B | $16.97B | $3.72B | $112.69B |
| Revenue (TTM) | $5.83B | $1.37B | $4.13B | $1.54B | $25.12B |
| Net Income (TTM) | $708M | $55M | $544M | $139M | $3.25B |
| Gross Margin | 44.1% | 53.6% | 52.8% | 48.7% | 63.5% |
| Operating Margin | 17.2% | 11.3% | 17.5% | 12.2% | 22.4% |
| Forward P/E | 21.0x | 8.7x | 17.2x | 15.5x | 19.6x |
| Total Debt | $2.20B | $835M | $2.63B | $898M | $14.86B |
| Cash & Equiv. | $172M | $41M | $1.96B | $449M | $4.01B |
STE vs CNMD vs HOLX vs MMSI vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| STERIS plc (STE) | 100 | 128.8 | +28.8% |
| CONMED Corporation (CNMD) | 100 | 51.9 | -48.1% |
| Hologic, Inc. (HOLX) | 100 | 142.6 | +42.6% |
| Merit Medical Syste… (MMSI) | 100 | 138.5 | +38.5% |
| Stryker Corporation (SYK) | 100 | 150.3 | +50.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: STE vs CNMD vs HOLX vs MMSI vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
STE is the clearest fit if your priority is long-term compounding.
- 220.0% 10Y total return vs SYK's 187.1%
CNMD is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.24 vs STE's 3.86
- Lower P/E (8.7x vs 19.6x), PEG 0.24 vs 1.32
- 2.1% yield, 2-year raise streak, vs SYK's 1.1%, (2 stocks pay no dividend)
HOLX carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
- Beta 0.41, current ratio 3.75x
- 13.2% margin vs CNMD's 4.0%
- Beta 0.41 vs CNMD's 1.34, lower leverage
MMSI ranks third and is worth considering specifically for growth exposure.
- Rev growth 11.7%, EPS growth 4.9%, 3Y rev CAGR 9.6%
- 11.7% revenue growth vs HOLX's 1.7%
SYK is the clearest fit if your priority is income & stability.
- Dividend streak 34 yrs, beta 0.55, yield 1.1%
- 6.9% ROA vs CNMD's 2.4%, ROIC 11.4% vs 5.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.7% revenue growth vs HOLX's 1.7% | |
| Value | Lower P/E (8.7x vs 19.6x), PEG 0.24 vs 1.32 | |
| Quality / Margins | 13.2% margin vs CNMD's 4.0% | |
| Stability / Safety | Beta 0.41 vs CNMD's 1.34, lower leverage | |
| Dividends | 2.1% yield, 2-year raise streak, vs SYK's 1.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +37.1% vs MMSI's -33.8% | |
| Efficiency (ROA) | 6.9% ROA vs CNMD's 2.4%, ROIC 11.4% vs 5.8% |
STE vs CNMD vs HOLX vs MMSI vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
STE vs CNMD vs HOLX vs MMSI vs SYK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SYK leads in 2 of 6 categories
CNMD leads 1 • STE leads 1 • HOLX leads 1 • MMSI leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SYK leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 18.3x CNMD's $1.4B. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to CNMD's 4.0%. On growth, SYK holds the edge at +11.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $5.8B | $1.4B | $4.1B | $1.5B | $25.1B |
| EBITDAEarnings before interest/tax | $1.4B | $219M | $974M | $290M | $6.3B |
| Net IncomeAfter-tax profit | $708M | $55M | $544M | $139M | $3.2B |
| Free Cash FlowCash after capex | $917M | $124M | $1000M | $274M | $4.3B |
| Gross MarginGross profit ÷ Revenue | +44.1% | +53.6% | +52.8% | +48.7% | +63.5% |
| Operating MarginEBIT ÷ Revenue | +17.2% | +11.3% | +17.5% | +12.2% | +22.4% |
| Net MarginNet income ÷ Revenue | +12.1% | +4.0% | +13.2% | +9.0% | +12.9% |
| FCF MarginFCF ÷ Revenue | +15.7% | +9.0% | +24.2% | +17.8% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +9.2% | -0.7% | +2.5% | +7.8% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +12.0% | +136.8% | -9.2% | +38.8% | +56.0% |
Valuation Metrics
CNMD leads this category, winning 7 of 7 comparable metrics.
Valuation Metrics
At 25.2x trailing earnings, CNMD trades at a 28% valuation discount to SYK's 35.0x P/E. Adjusting for growth (PEG ratio), CNMD offers better value at 0.69x vs STE's 6.35x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $21.0B | $1.2B | $17.0B | $3.7B | $112.7B |
| Enterprise ValueMkt cap + debt − cash | $23.0B | $2.0B | $17.6B | $4.2B | $123.5B |
| Trailing P/EPrice ÷ TTM EPS | 34.46x | 25.22x | 30.53x | 29.26x | 35.03x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.95x | 8.71x | 17.21x | 15.46x | 19.62x |
| PEG RatioP/E ÷ EPS growth rate | 6.35x | 0.69x | — | — | 2.36x |
| EV / EBITDAEnterprise value multiple | 17.15x | 10.17x | 17.39x | 13.06x | 20.31x |
| Price / SalesMarket cap ÷ Revenue | 3.85x | 0.85x | 4.14x | 2.45x | 4.49x |
| Price / BookPrice ÷ Book value/share | 3.20x | 1.15x | 3.43x | 2.38x | 5.02x |
| Price / FCFMarket cap ÷ FCF | 27.00x | 7.78x | 18.44x | 17.24x | 26.31x |
Profitability & Efficiency
SYK leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $5 for CNMD. STE carries lower financial leverage with a 0.33x debt-to-equity ratio, signaling a more conservative balance sheet compared to CNMD's 0.81x. On the Piotroski fundamental quality scale (0–9), STE scores 8/9 vs CNMD's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.9% | +5.4% | +11.0% | +8.9% | +15.0% |
| ROA (TTM)Return on assets | +6.7% | +2.4% | +6.1% | +5.2% | +6.9% |
| ROICReturn on invested capital | +7.2% | +5.8% | +9.4% | +7.2% | +11.4% |
| ROCEReturn on capital employed | +9.0% | +7.0% | +8.8% | +7.9% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 5 | 7 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.33x | 0.81x | 0.52x | 0.57x | 0.66x |
| Net DebtTotal debt minus cash | $2.0B | $794M | $667M | $450M | $10.8B |
| Cash & Equiv.Liquid assets | $172M | $41M | $2.0B | $449M | $4.0B |
| Total DebtShort + long-term debt | $2.2B | $835M | $2.6B | $898M | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | 15.94x | 5.20x | 8.00x | 10.74x | 6.72x |
Total Returns (Dividends Reinvested)
STE leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SYK five years ago would be worth $12,152 today (with dividends reinvested), compared to $2,902 for CNMD. Over the past 12 months, HOLX leads with a +37.1% total return vs MMSI's -33.8%. The 3-year compound annual growth rate (CAGR) favors STE at 5.3% vs CNMD's -31.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -14.3% | -6.0% | +1.9% | -27.9% | -15.2% |
| 1-Year ReturnPast 12 months | -3.9% | -31.3% | +37.1% | -33.8% | -22.5% |
| 3-Year ReturnCumulative with dividends | +16.6% | -67.3% | -8.5% | -26.5% | +5.5% |
| 5-Year ReturnCumulative with dividends | +5.9% | -71.0% | +15.8% | -3.6% | +21.5% |
| 10-Year ReturnCumulative with dividends | +220.0% | +6.6% | +124.3% | +214.6% | +187.1% |
| CAGR (3Y)Annualised 3-year return | +5.3% | -31.1% | -2.9% | -9.8% | +1.8% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than CNMD's 1.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs MMSI's 62.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.69x | 1.34x | 0.41x | 0.71x | 0.55x |
| 52-Week HighHighest price in past year | $269.44 | $61.08 | $76.04 | $100.19 | $404.87 |
| 52-Week LowLowest price in past year | $204.81 | $33.21 | $52.81 | $59.74 | $289.91 |
| % of 52W HighCurrent price vs 52-week peak | +79.3% | +62.4% | +100.0% | +62.2% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 41.2 | 49.6 | 69.1 | 34.9 | 24.3 |
| Avg Volume (50D)Average daily shares traded | 710K | 406K | 10.0M | 769K | 2.1M |
Analyst Outlook
Evenly matched — CNMD and SYK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: STE as "Buy", CNMD as "Hold", HOLX as "Hold", MMSI as "Buy", SYK as "Buy". Consensus price targets imply 104.8% upside for CNMD (target: $78) vs 3.9% for HOLX (target: $79). For income investors, CNMD offers the higher dividend yield at 2.09% vs STE's 1.04%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $256.67 | $78.00 | $79.00 | $95.00 | $403.69 |
| # AnalystsCovering analysts | 13 | 21 | 42 | 13 | 50 |
| Dividend YieldAnnual dividend ÷ price | +1.0% | +2.1% | — | — | +1.1% |
| Dividend StreakConsecutive years of raises | 14 | 2 | — | — | 34 |
| Dividend / ShareAnnual DPS | $2.22 | $0.79 | — | — | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.0% | 0.0% | +4.4% | 0.0% | 0.0% |
SYK leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CNMD leads in 1 (Valuation Metrics). 1 tied.
STE vs CNMD vs HOLX vs MMSI vs SYK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is STE or CNMD or HOLX or MMSI or SYK a better buy right now?
For growth investors, Merit Medical Systems, Inc.
(MMSI) is the stronger pick with 11. 7% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). CONMED Corporation (CNMD) offers the better valuation at 25. 2x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate STERIS plc (STE) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — STE or CNMD or HOLX or MMSI or SYK?
On trailing P/E, CONMED Corporation (CNMD) is the cheapest at 25.
2x versus Stryker Corporation at 35. 0x. On forward P/E, CONMED Corporation is actually cheaper at 8. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CONMED Corporation wins at 0. 24x versus STERIS plc's 3. 86x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — STE or CNMD or HOLX or MMSI or SYK?
Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.
5%, compared to -71. 0% for CONMED Corporation (CNMD). Over 10 years, the gap is even starker: STE returned +220. 0% versus CNMD's +6. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — STE or CNMD or HOLX or MMSI or SYK?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus CONMED Corporation's 1. 34β — meaning CNMD is approximately 225% more volatile than HOLX relative to the S&P 500. On balance sheet safety, STERIS plc (STE) carries a lower debt/equity ratio of 33% versus 81% for CONMED Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — STE or CNMD or HOLX or MMSI or SYK?
By revenue growth (latest reported year), Merit Medical Systems, Inc.
(MMSI) is pulling ahead at 11. 7% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: STERIS plc grew EPS 62. 7% year-over-year, compared to -64. 6% for CONMED Corporation. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — STE or CNMD or HOLX or MMSI or SYK?
Hologic, Inc.
(HOLX) is the more profitable company, earning 13. 8% net margin versus 3. 4% for CONMED Corporation — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus 10. 3% for CNMD. At the gross margin level — before operating expenses — SYK leads at 64. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is STE or CNMD or HOLX or MMSI or SYK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, CONMED Corporation (CNMD) is the more undervalued stock at a PEG of 0. 24x versus STERIS plc's 3. 86x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CONMED Corporation (CNMD) trades at 8. 7x forward P/E versus 21. 0x for STERIS plc — 12. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CNMD: 104. 8% to $78. 00.
08Which pays a better dividend — STE or CNMD or HOLX or MMSI or SYK?
In this comparison, CNMD (2.
1% yield), SYK (1. 1% yield), STE (1. 0% yield) pay a dividend. HOLX, MMSI do not pay a meaningful dividend and should not be held primarily for income.
09Is STE or CNMD or HOLX or MMSI or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, CNMD: +6. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between STE and CNMD and HOLX and MMSI and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
STE, CNMD, SYK pay a dividend while HOLX, MMSI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.